Production (Stage)
Haemonetics Corporation
HAE
$66.06
-$0.10-0.15%
NYSE
| 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 330.60M | 348.54M | 345.51M | 336.17M | 343.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 330.60M | 348.54M | 345.51M | 336.17M | 343.29M |
| Cost of Revenue | 131.44M | 148.63M | 154.31M | 151.64M | 154.35M |
| Gross Profit | 199.16M | 199.92M | 191.20M | 184.53M | 188.94M |
| SG&A Expenses | 116.69M | 105.74M | 104.72M | 91.58M | 115.12M |
| Depreciation & Amortization | 11.30M | 12.23M | 12.26M | 12.47M | 10.43M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 273.74M | 282.43M | 287.82M | 270.14M | 293.89M |
| Operating Income | 56.86M | 66.11M | 57.69M | 66.03M | 49.40M |
| Income Before Tax | 70.74M | 49.92M | 44.70M | 46.71M | 23.41M |
| Income Tax Expenses | 12.76M | 12.42M | 10.87M | 8.34M | 3.05M |
| Earnings from Continuing Operations | 57.98M | 37.49M | 33.83M | 38.37M | 20.37M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.98M | 37.49M | 33.83M | 38.37M | 20.37M |
| EBIT | 56.86M | 66.11M | 57.69M | 66.03M | 49.40M |
| EBITDA | 78.37M | 95.14M | 86.91M | 95.17M | 68.44M |
| EPS Basic | 1.18 | 0.75 | 0.66 | 0.75 | 0.40 |
| Normalized Basic EPS | 0.55 | 0.71 | 0.62 | 0.90 | 0.53 |
| EPS Diluted | 1.18 | 0.74 | 0.66 | 0.74 | 0.40 |
| Normalized Diluted EPS | 0.55 | 0.70 | 0.62 | 0.88 | 0.52 |
| Average Basic Shares Outstanding | 49.19M | 50.29M | 50.90M | 50.94M | 50.79M |
| Average Diluted Shares Outstanding | 49.48M | 50.64M | 51.24M | 51.56M | 51.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |